# Codexis Keeps 2026 Revenue Outlook at $72 Million to $76 Million

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/56171
Published: 2026-11-13T02:01:32.000Z
Updated: 2026-11-13T02:01:32.000Z
Section: Business

> The company reported third-quarter revenue of $19.3 million and expects its cash to fund planned operations and capital spending through 2028.

Codexis, Inc. kept its 2026 revenue outlook at $72 million to $76 million as it advances ECO Synthesis toward larger production runs and a pilot-scale transfer to a biopharmaceutical customer. The company also expects its full-year gross margin to be in the low 70s.

Third-quarter revenue was $19.3 million. Codexis described the quarter’s revenue as on target, while maintaining its annual range. The outlook covers the full year and is separate from the revenue recorded in the third quarter.

Cash and investments totaled $72.7 million at the end of the quarter, after financing and refinancing activity. Codexis expects its cash to fund planned operating costs and capital expenditures through 2028.

ECO Synthesis is Codexis’ enzymatic production process for oligonucleotide medicines. The company completed a 100-gram scale-up and is working toward production at 500 grams. It is also preparing a pilot-scale transfer of the process to a biopharmaceutical customer.

Codexis is continuing scale-up and supply-chain work as customer discussions move toward deployment. The timing of larger deals remains difficult to predict, and expanding production to kilogram quantities and beyond presents an execution challenge. The company is also emphasizing expense control as it develops the process.

The update pairs a maintained revenue target and a cash runway extending through 2028 with ongoing technical and customer work.